ReviewCancer immunology, immunotherapy : CII2006
Targeted and shielded adenovectors for cancer therapy.
Review in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Bioorthogonal Surface Modification of Measles and Vaccinia Viruses Using Metabolic Azide Reporters.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.Frontiers in immunology · 2024Review
- Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation.Molecular therapy oncolytics · 2021Article
- Species D Adenoviruses as Oncolytic Viral Vectors.Viruses · 2020Article
- Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Oncotarget · 2017Review
- Adenoviral vectors for prodrug activation-based gene therapy for cancer.Anti-cancer agents in medicinal chemistry · 2014Review
- Adenovirus: the first effective in vivo gene delivery vector.Human gene therapy · 2014Review
- Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.Journal of molecular biochemistry · 2012Article
- Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging.PloS one · 2011Article
- Chemoselective attachment of small molecule effector functionality to human adenoviruses facilitates gene delivery to cancer cells.Journal of the American Chemical Society · 2010Article
- Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.BMC cancer · 2010Article
- Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.Cancer gene therapy · 2010Article
- Current issues and future directions of oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.Cancer gene therapy · 2009Article
- Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.Journal of molecular biology · 2009Article
- Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.Gene therapy · 2009Article
- Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.PloS one · 2009Article
- PET imaging of thymidine kinase gene expression in the liver of non-human primates following systemic delivery of an adenoviral vector.Gene therapy · 2009Article
- Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.Gene therapy · 2008Article
- Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.Biochemistry insights · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conditionally replicative adenovirus (CRAd) vectors are novel vectors with utility as virotherapy agents for alternative cancer therapies. These vectors have already established a broad safety record in humans and overcome some of the limitations of non-replicative adenovirus (Ad) vectors. In addition, one potential problem with these vectors, attainment of tumor or tissue selectivity has widely been addressed. However, two confounding problems limiting efficacy of these drug candidates remains. The paucity of the native Ad receptor on tumor tissues, and host humoral response due to pre-existing titers of neutralizing antibodies against the vector itself in humans have been highlighted in the clinical context. The well-characterized CRAd, AdDelta24-RGD, is infectivity enhanced, thus overcoming the lack of coxsackievirus and adenovirus receptor (CAR), and this agent is already rapidly progressing towards clinical translation. However, the perceived host humoral response potentially will limit gains seen from the infectivity enhancement and therefore a strategy to blunt immunity against the vector is required. On the basis of this caveat a novel strategy, termed shielding, has been developed in which the genetic modification of a virion capsid protein would provide uniformly shielded Ad vectors. The identification of the pIX capsid protein as an ideal locale for genetic incorporation of shielding ligands to conceal the Ad vector from pre-existing neutralizing antibodies is a major progression in the development of shielded CRAds. Preliminary data utilizing an Ad vector with HSV-TK fused to the pIX protein indicates that a shield against neutralizing antibodies can be achieved. The utility of various proteins as shielding molecules is currently being addressed. The creation of AdDelta24S-RGD, an infectivity enhanced and shielded Ad vector will provide the next step in the development of clinically and commercially feasible CRAds that can be dosed multiple times for maximum effectiveness in the fight against cancers in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.